Corvus Pharmaceuticals, Inc.

Corvus Pharmaceuticals Misses on Revenue, Stock Down 0.52%

Corvus Pharmaceuticals reported an EPS of $-0.12, which was better than expected, but there was no revenue reported. The stock reacted by declining 0.52%, indicating that investors may have been looking for more clarity or stronger performance in other areas. The lack of guidance and management commentary may have contributed to the stock's negative reaction.